NCT00944892View on ClinicalTrials.gov

A Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Osteoarthritis of the Knee

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Osteoarthritis of the Knee
Interventions
DRUG

REGN475

2 Administrations of REGN475 within 24 weeks.

OTHER

Placebo

Placebo to match REGN475 doses

Trial Locations (3)

Unknown

Anaheim

Tampa

Salt Lake City

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Regeneron Pharmaceuticals

INDUSTRY

NCT00944892 - A Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Osteoarthritis of the Knee | Biotech Hunter | Biotech Hunter